|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
|
28786540 |
2017 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sustained response to standard dose osimertinib in a patient with plasma T790M-positive leptomeningeal metastases from primary lung adenocarcinoma.
|
28296233 |
2017 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel.
|
28193529 |
2017 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
The authors report two cases of epidermal growth factor receptor gene (EGFR)-mutant stage IV lung adenocarcinomas developing immunohistochemically proven squamous cell carcinoma (SCC) "transformation" concurrently with T790M EGFR mutation, leading to acquired resistance to EGFR inhibitors.
|
26746366 |
2016 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.
|
28662863 |
2017 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma.
|
27486808 |
2016 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
It suggests that T790M is possibly significant not only for EGFR TKI resistance but also the progression in lung adenocarcinoma.
|
29887244 |
2018 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.
|
30444875 |
2018 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
We showed a dramatic tumor response with cetuximab in an exon 19 deletion/T790M EGFR mutant lung adenocarcinoma PDX model, which suggests a role for the autocrine feedback loop in the mutant EGFR signaling pathway.
|
26926157 |
2016 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>EGFR</i> L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib.
|
31205925 |
2019 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
These observations unveiled the significance of YAP1 in EGFR mutant lung adenocarcinomas and identified YAP1 as a promising therapeutic target for EGFR-dependent lung adenocarcinoma patients, including those with EGFR T790M-caused TKI resistance.
|
29163769 |
2017 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Both agents were effective in multiple mouse xenograft models of human lung adenocarcinoma (T790M-positive or -negative), exhibiting less activity against wild-type EGFR than existing approved EGFR kinase inhibitors (including osimertinib).
|
28082405 |
2017 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Plasma samples from patients with advanced EGFR-mutated lung adenocarcinoma were analyzed for EGFR T790M, exon 19 deletions, and L858R mutations by both ddPCR and Cobas.
|
30810887 |
2019 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
|
27384480 |
2016 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>EGFR</i> T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing.
|
31737495 |
2019 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Lower pre-treatment PD-L1 is associated with better ORR, PFS, and higher frequency of T790M resistance in EGFR TKI-treated lung ADC patients.
|
31760310 |
2020 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among them, 41 patients with <i>EGFR</i>-mutant lung adenocarcinoma and EGFR-TKI progression were selected for an investigation of T790M mutation prevalence at rebiopsy.
|
29581791 |
2018 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Squamous cell transformation and <i>EGFR</i> T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.
|
29113230 |
2017 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is associated with approximately half of cases of acquired resistance to the EGFR kinase inhibitors, gefitinib and erlotinib.
|
18093943 |
2007 |
|
rs121434569
|
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR T790M mutation and cMET amplification are main mechanisms leading to EGFR TKI resistance in lung adenocarcinoma.
|
29616327 |
2018 |